RAB9A: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Disorders

Target Name: RAB9A

NCBI ID: G9367

RAB9A

RAB9A: A Potential Drug Target and Biomarker for Cancer and Neurodegenerative Disorders

Ras (Ras-related Rabbit2) is a gene that has been implicated in numerous diseases, including cancer, neurodegenerative disorders, and developmental defects. The RAS gene has four splice variants, RAB9A, RAB9B, RAB11A, and RAB11B. RAB9A is one of the most abundant splice variants and is widely expressed in various tissues. The RAB9A gene has been implicated in the development and progression of various diseases, including cancer, neurodegenerative disorders, and developmental defects. In this article, we will discuss the RAB9A gene and its potential as a drug target or biomarker.

Structure and Expression

The RAB9A gene is located on chromosome 12q34 and has four exons (1-4) with the last exon being a splice enhancer. The RAB9A gene has a calculated gene length of 1,284 base pairs (bp) and an estimated exon-intron ratio of 12.8 :1:1:1.

Expression of RAB9A

RAB9A is a highly expressed gene in various tissues, including muscle, heart, brain, and cancer. The RAB9A gene has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. RAB9A has also been shown to be expressed in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its expression in neurodegenerative disorders, RAB9A has also been shown to be involved in the development of various types of cancer. For example, studies have shown that RAB9A is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. . RAB9A has also been shown to be involved in the development of neuroblastoma, which is a type of cancer that affects children.

Drug Target Potential

RAB9A has been shown to be involved in several cellular processes that are important for cancer growth and progression. One of the most promising aspects of RAB9A is its potential as a drug target.

The RAB9A gene has been shown to be involved in the production of various proteins that are involved in cell signaling pathways, including the TGF-β pathway. TGF-β is a well-known protein that is involved in cell signaling and is a key regulator of cell growth and differentiation.

In addition to its involvement in the TGF-β pathway, RAB9A has also been shown to be involved in the production of other proteins that are involved in cell signaling pathways, including the NF-kappa-B pathway and the PI3K/Akt pathway. These pathways are important for cell signaling and are involved in various cellular processes, including cell growth, differentiation, and inflammation.

Given its involvement in these signaling pathways, RAB9A has potential as a drug target for a variety of diseases, including cancer and neurodegenerative disorders. One potential drug target for RAB9A is the use of small molecules that can inhibit the activity of RAB9A and its downstream signaling pathways.

Biomarker Potential

RAB9A has also been shown to be involved in the development and progression of various diseases, including cancer and neurodegenerative disorders. This suggests that RAB9A may be a useful biomarker for the diagnosis and treatment of these diseases.

For example, RAB9A has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. It is possible that RAB9A may be a useful biomarker for the diagnosis and treatment of these disorders.

In addition to its involvement in neurodegenerative disorders, RAB9A has also been shown to be involved in the development of certain types of cancer. For example, studies have shown that RAB9A is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. . This suggests that RAB9A may be a useful biomarker for the diagnosis and treatment of

Protein Name: RAB9A, Member RAS Oncogene Family

Functions: Involved in the transport of proteins between the endosomes and the trans Golgi network. Involved in the recruitment of SGSM2 to melanosomes and is required for the proper trafficking of melanogenic enzymes TYR, TYRP1 and DCT/TYRP2 to melanosomes in melanocytes

The "RAB9A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB9A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets